BRCA2 and pachyonychia congenita: Moreover, treatment resistance in PC is a multifactorial process involving diverse molecular pathways; thus, it will be crucial to investigate how GSTM5 interacts with other resistance pathways, such as alterations in BRCA2, TP53, and PTEN, which have been shown to influence therapeutic response [30].